All In Biotech

Drug Trial Radar · NCT05987241

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 992 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

992

Planned (sponsor's estimate)

Start

Feb 2, 2024

Primary completion

Sep 2, 2030

Study completion Sep 2, 2030

Sponsor

Sponsor type
NIH
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.

Conditions

  • Muscle Invasive Bladder Urothelial Carcinoma
  • Muscle Invasive Renal Pelvis Urothelial Carcinoma
  • Muscle Invasive Ureter Urothelial Carcinoma
  • Muscle Invasive Urethral Urothelial Carcinoma
  • Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage IV Bladder Urothelial Carcinoma AJCC v7

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of tissue and blood

  • cfDNA or ctDNA MeasurementOther

    Undergo ctDNA surveillance

  • Computed TomographyProcedure

    Undergo CT

  • CystoscopyProcedure

    Undergo cystoscopy

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • NivolumabBiological

    Given IV

  • Questionnaire AdministrationOther

    Ancillary studies

  • RelatlimabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients who are circulating tumor DNA negative (ctDNA[-]) (Cohort A Phase II)Time frame: At week 12 from treatment start date
  2. Overall survival (OS) (Cohort A Phase III)Time frame: From randomization until death due to any cause, assessed up to 5 years after completion of study treatment
  3. Disease-Free Survival (DFS) (Cohort B)Time frame: From randomization until confirmed disease recurrence as assessed by the treating physician or death due to any cause, assessed up to 5 years after completion of study treatment

Locations

505 sites in 2 countries. Site status is shown where the registry gives one.

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona · Recruiting

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona · Recruiting

  • University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona · Suspended

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • Highlands Oncology Group - Fayetteville

    Fayetteville, Arkansas · Recruiting

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • Kaiser Permanente-Anaheim

    Anaheim, California · Recruiting

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California · Recruiting

  • Kaiser Permanente-Bellflower

    Bellflower, California · Recruiting

  • Kaiser Permanente Dublin

    Dublin, California · Recruiting

  • Kaiser Permanente-Fontana

    Fontana, California · Recruiting

  • Kaiser Permanente-Fremont

    Fremont, California · Recruiting

  • Kaiser Permanente Fresno Orchard Plaza

    Fresno, California · Recruiting

  • Kaiser Permanente-Fresno

    Fresno, California · Recruiting

  • Kaiser Permanente South Bay

    Harbor City, California · Recruiting

  • Kaiser Permanente-Irvine

    Irvine, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • Keck Medicine of USC Koreatown

    Los Angeles, California · Active not recruiting

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California · Recruiting

  • Los Angeles General Medical Center

    Los Angeles, California · Active not recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Active not recruiting

  • Kaiser Permanente West Los Angeles

    Los Angeles, California · Recruiting

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente- Modesto MOB II

    Modesto, California · Recruiting

  • Kaiser Permanente-Modesto

    Modesto, California · Recruiting

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California · Active not recruiting

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • Kaiser Permanente-Ontario

    Ontario, California · Recruiting

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California · Recruiting

  • Kaiser Permanente - Panorama City

    Panorama City, California · Recruiting

  • Kaiser Permanente-Riverside

    Riverside, California · Recruiting

  • Kaiser Permanente-Roseville

    Roseville, California · Recruiting

  • Kaiser Permanente Downtown Commons

    Sacramento, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Kaiser Permanente-South Sacramento

    Sacramento, California · Recruiting

  • Kaiser Permanente-San Diego Zion

    San Diego, California · Recruiting

  • Kaiser Permanente-San Francisco

    San Francisco, California · Recruiting

  • Kaiser Permanente-Santa Teresa-San Jose

    San Jose, California · Recruiting

Showing 40 of 505 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.